Voyager Therapeutics, Inc. (VYGR) Stifel 2026 Virtual CNS Forum March 18, 2026 12:30 PM EDT
Company Participants
Alfred Sandrock – President, CEO & Director
Conference Call Participants
Paul Matteis
Presentation
Paul Matteis
Great. Thanks very much. It’s my pleasure to be moderating this chat with the CEO of Voyager Therapeutics, Al Sandrock, who sure many folks know well from his current role and famous roles as prior. Al, maybe we can get into it and talk more about Voyager and some of the key events this year for you guys in the broader neuro space. If you want to just give a quick snapshot of 2025 as a year for Voyager and the key things that people should be focused on, and then we’ll do more specifics?
Alfred Sandrock
President, CEO & Director
Yes. So first of all, we have — we’ve been calling it the year of tau. We have 2 assets directed against tau. We have — 1 is an antibody, a C-terminal antibody that we expect to get tau PET imaging data by the end of the year in a multiple ascending dose study. And then the second is the gene therapy tau knockdown asset, very much akin to BIIB080 which, by the way, has a pretty important readout coming up midyear time frame.
Second sort of pillar of value would be that we get — this is the first year that we put our capsids, our newly discovered BBB penetrant capsids into the clinic. And we have 2 assets doing that. One is the tau knock down gene therapy, I just mentioned, but the other 1 is a neurocrine partnered program for Friedreich’s ataxia. So we should be getting set up, if you will, this year for getting a proof of concept that our capsids can work and produce gene expression broadly in the
Credit: Source link
